Covis patents expiration
1. Altoprev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5916595 | COVIS | HMG co-reductase inhibitor |
Dec, 2017
(6 years ago) | |
| US6485748 | COVIS | Once daily pharmaceutical tablet having a unitary core |
Dec, 2017
(6 years ago) | |
| US6080778 | COVIS | Methods for decreasing beta amyloid protein |
Mar, 2018
(6 years ago) | |
Drugs and Companies using LOVASTATIN ingredient
Market Authorisation Date: 26 June, 2002
Treatment: Method of decreasing the production of a-beta using a composition which decreases blood cholesterol in patients at risk of or exhibiting symptoms of alzheimer's disease
Dosage: TABLET, EXTENDED RELEASE;ORAL
ALTOPREV family patents
2. Alvesco patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6036942 | COVIS | Seal configuration for aerosol canister |
Apr, 2013
(11 years ago) | |
| US5605674 | COVIS | Medicinal aerosol formulations |
Feb, 2014
(10 years ago) | |
| US5683677 | COVIS | Medicinal aerosol formulations |
Nov, 2014
(9 years ago) | |
| US5775321 | COVIS | Seal configuration for aerosol canister |
Jul, 2015
(8 years ago) | |
| US6006745 | COVIS | Device for delivering an aerosol |
Dec, 2016
(7 years ago) | |
| US6264923 | COVIS | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(5 years ago) | |
| US6120752 | COVIS | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(5 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
| M(M-125) | Dec 17, 2015 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 10 January, 2008
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child; Method of treati...
Dosage: AEROSOL, METERED;INHALATION
ALVESCO family patents
3. Duaklir Pressair patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US8129405 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US7750023 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(1 year, 8 months ago) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(2 years from now) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic pulmonary disease (copd)
Dosage: POWDER, METERED;INHALATION
DUAKLIR PRESSAIR family patents
4. Feraheme patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7553479 | COVIS | Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof |
Mar, 2020
(4 years ago) | |
| US8926947 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| US7871597 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| US6599498 | COVIS | Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives |
Jun, 2023
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501158 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| US8591864 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 30, 2012 |
| New Indication(I-767) | Feb 02, 2021 |
Drugs and Companies using FERUMOXYTOL ingredient
Market Authorisation Date: 30 June, 2009
Treatment: Method of treating patients needing an iron supplement
Dosage: SOLUTION;INTRAVENOUS
FERAHEME family patents
5. Makena (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE44846 | COVIS | Needle assisted jet injector |
Aug, 2019
(4 years ago) | |
| US9533102 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 8 months from now) | |
| US9629959 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 8 months from now) | |
| US9180259 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 8 months from now) | |
| US11446441 | COVIS | Prefilled syringe injector |
Jan, 2026
(1 year, 8 months from now) | |
| US8562564 | COVIS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 8 months from now) | |
| US8021335 | COVIS | Prefilled syringe jet injector |
Oct, 2026
(2 years from now) | |
| US11446440 | COVIS | Needle assisted injection device having reduced trigger force |
Aug, 2031
(7 years from now) | |
| US9789257 | COVIS | Needle assisted injection device having reduced trigger force |
Feb, 2034
(9 years from now) | |
| US11154562 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
| US10471075 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
| US11304962 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
| US9844558 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 03, 2018 |
| Orphan Drug Exclusivity(ODE-7) | Feb 03, 2018 |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 14 February, 2018
Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
Dosage: SOLUTION;SUBCUTANEOUS
MAKENA (AUTOINJECTOR) family patents
6. Omnaris patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7235247 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(5 years ago) | |
| US6939559 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(5 years ago) | |
| US8383611 | COVIS | Ciclesonide containing aqueous pharmaceutical composition |
Oct, 2020
(3 years ago) | |
| US6767901 | COVIS | Ciclesonide contained pharmaceutical composition for application to mucosa |
Oct, 2020
(3 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 20 October, 2006
Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults a...
Dosage: SPRAY, METERED;NASAL
OMNARIS family patents
7. Prilosec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5900424 | COVIS | Omeprazole magnesium salt form |
May, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5690960 | COVIS | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
| US6428810 | COVIS | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using OMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 20 March, 2008
Treatment: Pediatric use ages 1-2 years, gerd and erosive esophagitis; Pediatric use ages 1 month to 2 years, gerd and erosive esophagitis
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
PRILOSEC family patents
8. Rilutek patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5527814 | COVIS | Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis |
Jun, 2013
(10 years ago) | |
Drugs and Companies using RILUZOLE ingredient
Market Authorisation Date: 12 December, 1995
Treatment: NA
Dosage: TABLET;ORAL
RILUTEK family patents
9. Sular patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5626874 | COVIS | Controlled release pharmaceutical tablet having lenticular form |
Nov, 2014
(9 years ago) | |
Drugs and Companies using NISOLDIPINE ingredient
Market Authorisation Date: 02 January, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
SULAR family patents
10. Tudorza Pressair patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US6750226 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep, 2020
(3 years ago) | |
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071498 | COVIS | Inhaler for powdered medicaments |
Jun, 2016
(7 years ago) | |
| US5840279 | COVIS | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun, 2016
(7 years ago) | |
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(1 year, 8 months ago) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(2 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-256) | Mar 29, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic obstructive pulmonary disease (copd); Maintenance treatment of chro...
Dosage: POWDER, METERED;INHALATION
TUDORZA PRESSAIR family patents
11. Zetonna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6036942 | COVIS | Seal configuration for aerosol canister |
Apr, 2013
(11 years ago) | |
| US5605674 | COVIS | Medicinal aerosol formulations |
Feb, 2014
(10 years ago) | |
| US5683677 | COVIS | Medicinal aerosol formulations |
Nov, 2014
(9 years ago) | |
| US5775321 | COVIS | Seal configuration for aerosol canister |
Jul, 2015
(8 years ago) | |
| US6006745 | COVIS | Device for delivering an aerosol |
Dec, 2016
(7 years ago) | |
| US6264923 | COVIS | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(5 years ago) | |
| US6120752 | COVIS | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(5 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 20, 2015 |
Drugs and Companies using CICLESONIDE ingredient
Market Authorisation Date: 20 January, 2012
Treatment: Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child;...
Dosage: AEROSOL, METERED;NASAL
ZETONNA family patents